GO
Loading...

Life Sciences

More

  • WHO: Ebola vaccine trials in W. Africa in January Tuesday, 21 Oct 2014 | 7:19 AM ET

    GENEVA— Tens of thousands of doses of experimental Ebola vaccines could be available for "real-world" testing in West Africa as soon as January as long as they are deemed safe, a top World Health Organization official said Tuesday. The Ebola outbreak in West Africa has already killed over 4,500 people, mostly in Liberia, Guinea and Sierra Leone, since it emerged 10...

  • SYDNEY, Oct 17- Australian biotech firm CSL Ltd, the world's second-biggest blood products maker, said on Friday it's working on a plasma product to treat Ebola following a request from the Bill& Melinda Gates Foundation, part of a growing commercial response to the deadly outbreak. Along with CSL, Sydney- listed protective products maker Ansell Ltd, the world's...

  • SYDNEY, Oct 17- Australian biotech firm CSL Ltd, the world's second-biggest blood products maker, said on Friday it's working on a plasma product to treat Ebola following a request from the Bill& Melinda Gates Foundation, part of a growing commercial response to the deadly outbreak. Along with CSL, Sydney- listed protective products maker Ansell Ltd, the world's...

  • Canadian Ebola vaccine begins testing Monday, 13 Oct 2014 | 11:40 AM ET

    TORONTO— Human testing of an experimental Canadian-made Ebola vaccine began Monday, with federal officials saying the drug could be shipped to West Africa within months if it proves successful. Health Minister Rona Ambrose said the launch of the vaccine's first clinical trial marks a promising step in the global campaign to contain the virus, which the World...

  • NEA, known for backing companies such as Workday Inc, Salesforce.com Inc and Gilt Groupe, is one of the world's top venture firms, with its latest fund totalling $2.6 billion. Health science is one area where women venture capitalists appear to be making serious gains, with some of the most accomplished health investors, including Beth Seidenberg of Kleiner...

  • Oct 6- After nearly a week in hospital, the first Ebola patient diagnosed in the United States began to receive an experimental therapy initially developed to treat other viral diseases, according to the Dallas hospital where he lies in critical condition. On Monday, however, a spokeswoman for Texas Health Presbyterian Hospital said Duncan began receiving a...

  • While Lilly's shares hardly budged on the news, the ADRs of Israel- based XTL Biopharmaceuticals Inc, which is developing its own lupus treatment, nearly tripled to $5.00. About 1.5 million people in the United States are estimated to suffer from lupus, according to the U.S. Centers of Disease Control and Prevention. The U.S. Food and Drug Administration approved...

  • Oct 1- An experimental cholesterol-fighting drug being developed by Esperion Therapeutics Inc lowered LDL levels significantly more than Merck& Co Inc's Zetia in a midstage clinical trial, Esperion said on Wednesday. The LDL reductions seen with the once-daily ETC-1002 pill were somewhat less than can be achieved by more powerful statins, such as Pfizer...

  • Oct 1- A new type of experimental cholesterol fighter being developed by Esperion Therapeutics Inc lowered LDL levels significantly more than Merck& Co Inc's Zetia in a midstage clinical trial, the company said on Wednesday.

  • NEW YORK, Oct. 1- Two tiny companies are preparing to challenge some of the world's largest drug makers in the battle for dominance in the $3 billion global market for influenza vaccines, armed with little more than tiny tobacco plants.

  • Sept 30- Johnson& Johnson said it would buy privately held drug developer Alios BioPharma Inc for $1.75 billion in cash, to access a portfolio of drugs targeting viral infections. Johnson& Johnson said the deal includes Alios's experimental drug for infants with respiratory syncytial virus.

  • MADRID, Sept 28- Merck& Co's drug Keytruda, the first in a new wave of immune-boosting medicines to be approved for treating melanomas in the United States, also has potential in stomach cancer, new research shows.

  • *AstraZeneca says tolerability profile encouraging. MADRID, Sept 27- Early results for a closely watched cancer drug combination from AstraZeneca that boosts the immune system suggest the cocktail is promising, though limited patient numbers mean the data is far from conclusive.

  • Inovio to start human trials of Ebola vaccine Wednesday, 24 Sep 2014 | 11:28 AM ET

    Sept 24- Vaccine developer Inovio Pharmaceuticals Inc said the company and its partner GeneOne Life Science Inc will start testing its experimental Ebola vaccine in humans in the first half of 2015.. Two other vaccine candidates in development are from GlaxoSmithKline Plc and NewLink Genetics Corp..

  • Record iPhone 6 sales would have been even better Monday, 22 Sep 2014 | 11:04 AM ET
    A customer looks at the new iPhone 6 Plus after it went on sale along with the iPhone 6 at the Apple Omotesando store in Tokyo, Sept. 19, 2014.

    In Monday's The Good, The Bad, and The Ugly: iPhone 6 sales top record; a poll shows attitudes towards corporations; and a German firm shops in U.S.

  • German firm buys American, but not for taxes: CEOs Monday, 22 Sep 2014 | 8:09 AM ET
    The Merck KGaA logo sits outside the company's headquarters in Darmstadt, Germany.

    Merck agrees to acquire Sigma-Aldrich for $17 billion in cash to boost its life science business.

  • PARIS, Sept 18- French cancer immunotherapy specialist OSE Pharma has registered with market regulator AMF for an initial public offering aimed at financing late-stage trials of its Texopi drug for the most common form of lung cancer, the company said on Thursday.

  • Sept 15- Epirus Biopharmaceuticals Inc said India's drug regulator has approved its copy of a top-selling arthritis treatment, paving the way for its launch in the country early next year.

  • NEW YORK, Sept 11- The highly anticipated debut of Alibaba Group Holding Ltd, the Chinese e-commerce group, will come amid the busiest year for initial public offerings since the technology bubble burst in 2000.. Alibaba's IPO, which could come as soon as Sept. 19, could raise more than $21 billion and claim Facebook Inc's title of biggest tech IPO.

  • Sept 5- Keryx Biopharmaceuticals Inc won U.S. approval for its drug to lower phosphate levels in patients with chronic kidney disease, but the approval included an unexpected safety warning on the label. However, the FDA- mandated label does not include the benefits of the drug in treating anemia.